Cargando…
A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic TFE3-rearranged renal cell carcinoma:a case report
TFE3-rearranged renal cell carcinoma (RCC) is a rare subtype of renal tumor that primarily affects young women and is characterized by early metastasis and a poor prognosis. This case study presents a 29-year-old woman diagnosed with TFE3-rearranged RCC, who initially presented with painless gross h...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627181/ https://www.ncbi.nlm.nih.gov/pubmed/37936602 http://dx.doi.org/10.3389/fonc.2023.1252282 |
_version_ | 1785131486806016000 |
---|---|
author | Yang, Haiyang Dong, Xiang Pan, Xinghe Ma, Wenliang Pan, Jun Guo, Hongqian Gan, Weidong |
author_facet | Yang, Haiyang Dong, Xiang Pan, Xinghe Ma, Wenliang Pan, Jun Guo, Hongqian Gan, Weidong |
author_sort | Yang, Haiyang |
collection | PubMed |
description | TFE3-rearranged renal cell carcinoma (RCC) is a rare subtype of renal tumor that primarily affects young women and is characterized by early metastasis and a poor prognosis. This case study presents a 29-year-old woman diagnosed with TFE3-rearranged RCC, who initially presented with painless gross hematuria. Computed Tomography (CT) imaging revealed the presence of a solid mass in the left kidney along with retroperitoneal metastasis. The patient received axitinib, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI), as first-line neoadjuvant therapy. Subsequent testing confirmed positive expression of programmed death-1 protein L1 (PDL1), leading to the addition of tislelizumab, a PD1 inhibitor, to the treatment regimen. After 8 months, the patient’s tumor size and metastases exhibited significant reduction, providing a favorable opportunity for subsequent surgical intervention. The tumor was classified as IV (pT3aN0M1) based on the pathologic stage of the American Joint Committee on Cancer (AJCC, 8th edition, 2017). The patient achieved long-term survival through combined systemic therapy involving surgery and neoadjuvant treatment. At the 30-month follow-up, there was no evidence of tumor recurrence or metastasis. |
format | Online Article Text |
id | pubmed-10627181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106271812023-11-07 A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic TFE3-rearranged renal cell carcinoma:a case report Yang, Haiyang Dong, Xiang Pan, Xinghe Ma, Wenliang Pan, Jun Guo, Hongqian Gan, Weidong Front Oncol Oncology TFE3-rearranged renal cell carcinoma (RCC) is a rare subtype of renal tumor that primarily affects young women and is characterized by early metastasis and a poor prognosis. This case study presents a 29-year-old woman diagnosed with TFE3-rearranged RCC, who initially presented with painless gross hematuria. Computed Tomography (CT) imaging revealed the presence of a solid mass in the left kidney along with retroperitoneal metastasis. The patient received axitinib, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI), as first-line neoadjuvant therapy. Subsequent testing confirmed positive expression of programmed death-1 protein L1 (PDL1), leading to the addition of tislelizumab, a PD1 inhibitor, to the treatment regimen. After 8 months, the patient’s tumor size and metastases exhibited significant reduction, providing a favorable opportunity for subsequent surgical intervention. The tumor was classified as IV (pT3aN0M1) based on the pathologic stage of the American Joint Committee on Cancer (AJCC, 8th edition, 2017). The patient achieved long-term survival through combined systemic therapy involving surgery and neoadjuvant treatment. At the 30-month follow-up, there was no evidence of tumor recurrence or metastasis. Frontiers Media S.A. 2023-10-23 /pmc/articles/PMC10627181/ /pubmed/37936602 http://dx.doi.org/10.3389/fonc.2023.1252282 Text en Copyright © 2023 Yang, Dong, Pan, Ma, Pan, Guo and Gan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yang, Haiyang Dong, Xiang Pan, Xinghe Ma, Wenliang Pan, Jun Guo, Hongqian Gan, Weidong A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic TFE3-rearranged renal cell carcinoma:a case report |
title | A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic TFE3-rearranged renal cell carcinoma:a case report |
title_full | A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic TFE3-rearranged renal cell carcinoma:a case report |
title_fullStr | A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic TFE3-rearranged renal cell carcinoma:a case report |
title_full_unstemmed | A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic TFE3-rearranged renal cell carcinoma:a case report |
title_short | A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic TFE3-rearranged renal cell carcinoma:a case report |
title_sort | safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic tfe3-rearranged renal cell carcinoma:a case report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627181/ https://www.ncbi.nlm.nih.gov/pubmed/37936602 http://dx.doi.org/10.3389/fonc.2023.1252282 |
work_keys_str_mv | AT yanghaiyang asafeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport AT dongxiang asafeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport AT panxinghe asafeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport AT mawenliang asafeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport AT panjun asafeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport AT guohongqian asafeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport AT ganweidong asafeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport AT yanghaiyang safeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport AT dongxiang safeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport AT panxinghe safeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport AT mawenliang safeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport AT panjun safeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport AT guohongqian safeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport AT ganweidong safeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport |